A group of compounding pharmacies has filed a lawsuit against the FDA, challenging the agency’s decision to remove semaglutide — which is used to treat Type 2 diabetes and obesity — from the drug shortage list.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
